These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23108403)

  • 1. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance.
    Ray-David H; Romeo Y; Lavoie G; Déléris P; Tcherkezian J; Galan JA; Roux PP
    Oncogene; 2013 Sep; 32(38):4480-9. PubMed ID: 23108403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic Analysis Reveals a Role for RSK in p120-catenin Phosphorylation and Melanoma Cell-Cell Adhesion.
    Méant A; Gao B; Lavoie G; Nourreddine S; Jung F; Aubert L; Tcherkezian J; Gingras AC; Roux PP
    Mol Cell Proteomics; 2020 Jan; 19(1):50-64. PubMed ID: 31678930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actin Dysfunction Induces Cell Cycle Delay at G2/M with Sustained ERK and RSK Activation in IMR-90 Normal Human Fibroblasts.
    Shrestha D; Choi D; Song K
    Mol Cells; 2018 May; 41(5):436-443. PubMed ID: 29754473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.
    Theodosakis N; Micevic G; Langdon CG; Ventura A; Means R; Stern DF; Bosenberg MW
    J Invest Dermatol; 2017 Oct; 137(10):2187-2196. PubMed ID: 28599981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of RSK substrates using an analog-sensitive kinase approach.
    Lizcano-Perret B; Vertommen D; Herinckx G; Calabrese V; Gatto L; Roux PP; Michiels T
    J Biol Chem; 2024 Mar; 300(3):105739. PubMed ID: 38342435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models.
    Sechi M; Lall RK; Afolabi SO; Singh A; Joshi DC; Chiu SY; Mukhtar H; Syed DN
    Sci Rep; 2018 Oct; 8(1):15726. PubMed ID: 30356079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling.
    Alasady MJ; Terry AR; Pierce AD; Cavalier MC; Blaha CS; Adipietro KA; Wilder PT; Weber DJ; Hay N
    PLoS One; 2021; 16(8):e0256238. PubMed ID: 34411141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies?
    Koutsougianni F; Alexopoulou D; Uvez A; Lamprianidou A; Sereti E; Tsimplouli C; Ilkay Armutak E; Dimas K
    Biochem Pharmacol; 2023 Apr; 210():115488. PubMed ID: 36889445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative feedback via RSK modulates Erk-dependent progression from naïve pluripotency.
    Nett IR; Mulas C; Gatto L; Lilley KS; Smith A
    EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29895711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation.
    Saha M; Carriere A; Cheerathodi M; Zhang X; Lavoie G; Rush J; Roux PP; Ballif BA
    Biochem J; 2012 Oct; 447(1):159-66. PubMed ID: 22827337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the RAS pathway in melanoma.
    Ji Z; Flaherty KT; Tsao H
    Trends Mol Med; 2012 Jan; 18(1):27-35. PubMed ID: 21962474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation-Assisted Luciferase Complementation Assay Designed to Monitor Kinase Activity and Kinase-Domain-Mediated Protein-Protein Binding.
    Póti ÁL; Dénes L; Papp K; Bató C; Bánóczi Z; Reményi A; Alexa A
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway.
    Achkar IW; Abdulrahman N; Al-Sulaiti H; Joseph JM; Uddin S; Mraiche F
    J Transl Med; 2018 Apr; 16(1):96. PubMed ID: 29642900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RIOK2 phosphorylation by RSK promotes synthesis of the human small ribosomal subunit.
    Cerezo EL; Houles T; Lié O; Sarthou MK; Audoynaud C; Lavoie G; Halladjian M; Cantaloube S; Froment C; Burlet-Schiltz O; Henry Y; Roux PP; Henras AK; Romeo Y
    PLoS Genet; 2021 Jun; 17(6):e1009583. PubMed ID: 34125833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophilic fragment-based design of reversible covalent kinase inhibitors.
    Miller RM; Paavilainen VO; Krishnan S; Serafimova IM; Taunton J
    J Am Chem Soc; 2013 Apr; 135(14):5298-301. PubMed ID: 23540679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribosomal S6 kinase signaling regulates neuronal viability during development and confers resistance to excitotoxic cell death in mature neurons.
    Hoyt KR; Horning P; Georgette Ang P; Karelina K; Obrietan K
    Neuroscience; 2024 Oct; 558():1-10. PubMed ID: 39137868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site matters in metastatic melanoma.
    Wilson HP; Aplin AE
    Trends Cancer; 2023 Aug; 9(8):603-605. PubMed ID: 37331825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine-kinase Inhibitors Treatment in Advanced Malignant Melanoma.
    Popescu A; Anghel RM
    Maedica (Bucur); 2017 Dec; 12(4):293-296. PubMed ID: 29610594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of p90 Ribosomal S6 Kinase (RSK) in Tyrosine Kinase Inhibitor (TKI)-Induced Cardiotoxicity.
    Suleiman M; Al Najjar A; Zakaria ZZ; Ahmed R; Yalcin HC; Korashy HM; Uddin S; Riaz S; Abdulrahman N; Mraiche F
    J Cardiovasc Transl Res; 2024 Apr; 17(2):334-344. PubMed ID: 37725271
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.